AIM ImmunoTech
Yahoo Finance • 2 years ago
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
- Live video webcast presentations with participating companies - FRENCHTOWN, NJ / ACCESSWIRE / January 11, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the... Full story
Yahoo Finance • 2 years ago
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 OCALA, Fla., Nov. 15, 2022 (GLOBE NEWS... Full story
Yahoo Finance • 2 years ago
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR)+ microinvasive residual d... Full story
Yahoo Finance • 2 years ago
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities Laws and SEC and Florida Injunc... Full story
Yahoo Finance • 3 years ago
AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference
OCALA, Fla., May 19, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune... Full story
Yahoo Finance • 3 years ago
AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program
OCALA, Fla., May 18, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune... Full story
